A Discussion with George Goldsmith & Ekaterina Malievskaia featuring Clara Burtenshaw
Clara Burtenshaw is a partner at Neo Kuma Ventures, Europe’s first and largest psychedelics focussed VC fund. Through its portfolio and lab, Neo Kuma is building a new paradigm of treatments that will advance and redefine patient care.’
Neo Kuma Ventures invests in market disruptors and category leaders at the forefront of psychedelic healthcare with investments spanning drug development, clinics, delivery and infrastructure including experiential platforms and digital therapeutics. Its mission is to find and build world class companies that will transform the healthcare sector and move the standard of patient care forwards.
In addition to investing, Neo Kuma Ventures collaborates closely with policy makers, scientific experts, academics, and media to explore how psychedelics can be integrated into primary and secondary healthcare. Their thought leadership pieces have been featured in publications such as Fortune, Business Insider and national press in the United Kingdom.
Prior to founding Neo Kuma Ventures, Clara served as General Counsel and senior management at a PE-backed major retail group. Clara began her career at a leading law firm and received degrees from Oxford University and NYU School of Law.